{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:34:03Z","timestamp":1781537643978,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RU5211 SOMACROSS (DFG project number 445297796)"],"award-info":[{"award-number":["RU5211 SOMACROSS (DFG project number 445297796)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FOR 2690 PruSearch (STA 1159\/4-2"],"award-info":[{"award-number":["FOR 2690 PruSearch (STA 1159\/4-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["STA 1159\/7-1)"],"award-info":[{"award-number":["STA 1159\/7-1)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s13555-025-01539-3","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T09:31:50Z","timestamp":1757928710000},"page":"3361-3375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative Analysis of Patient-Reported Outcomes in Chronic Pruritus: Patients with Chronic Liver or Kidney Diseases Exhibit Higher Psychological Distress than Those with Atopic Dermatitis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2118-959X","authenticated-orcid":false,"given":"Svenja","family":"Royeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8642-5226","authenticated-orcid":false,"given":"Christian","family":"Mess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6820-8316","authenticated-orcid":false,"given":"Angelika","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4220-3378","authenticated-orcid":false,"given":"Bernd","family":"L\u00f6we","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5189-6615","authenticated-orcid":false,"given":"Anne","family":"Toussaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-1928","authenticated-orcid":false,"given":"Christoph","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2023-3824","authenticated-orcid":false,"given":"Meike","family":"Shedden Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7175-5062","authenticated-orcid":false,"given":"Tobias B.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9485-8627","authenticated-orcid":false,"given":"Claudia","family":"Zeidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4305-0713","authenticated-orcid":false,"given":"Felix","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5601-9195","authenticated-orcid":false,"given":"Konstantin","family":"Agelopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6289-8600","authenticated-orcid":false,"given":"Henning","family":"Wiegmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4240-1809","authenticated-orcid":false,"given":"Johannes B.","family":"Oehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4679-7137","authenticated-orcid":false,"given":"Stefan W.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-7786","authenticated-orcid":false,"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"1539_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000319862","volume":"221","author":"S St\u00e4nder","year":"2010","unstructured":"St\u00e4nder S, Sch\u00e4fer I, Phan NQ, et al. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology. 2010;221:229\u201335.","journal-title":"Dermatology"},{"key":"1539_CR2","doi-asserted-by":"publisher","first-page":"175628482311728","DOI":"10.1177\/17562848231172829","volume":"16","author":"E Ebhohon","year":"2023","unstructured":"Ebhohon E, Chung RT. Systematic review: efficacy of therapies for cholestatic pruritus. Therap Adv Gastroenterol. 2023;16:17562848231172828.","journal-title":"Therap Adv Gastroenterol"},{"key":"1539_CR3","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2215\/CJN.0000000000000537","volume":"19","author":"KK Tennankore","year":"2024","unstructured":"Tennankore KK, McCullough K, Bieber B, et al. Prevalence and outcomes of chronic kidney disease-associated pruritus: international results from peritoneal dialysis outcomes and practice patterns study. Clin J Am Soc Nephrol. 2024;19:1622\u201334.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1539_CR4","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2147\/TCRM.S310550","volume":"17","author":"K \u015awierczy\u0144ska","year":"2021","unstructured":"\u015awierczy\u0144ska K, Bia\u0142ynicki-Birula R, Szepietowski JC. Chronic intractable pruritus in chronic kidney disease patients: prevalence, impact, and management challenges \u2013 a narrative review. Ther Clin Risk Manag. 2021;17:1267\u201382.","journal-title":"Ther Clin Risk Manag"},{"key":"1539_CR5","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1111\/jdv.19913","volume":"38","author":"C Zeidler","year":"2024","unstructured":"Zeidler C, Kupfer J, Dalgard FJ, et al. Dermatological patients with itch report more stress, stigmatization experience, anxiety and depression compared to patients without itch: results from a European multi-centre study. J Eur Acad Dermatol Venereol. 2024;38:1649\u201361.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1539_CR6","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/jdv.20102","volume":"38","author":"S St\u00e4nder","year":"2024","unstructured":"St\u00e4nder S, Pereira MP, Zeidler C, et al. EADV task force pruritus white paper on chronic pruritus and chronic prurigo: current challenges and future solutions. J Eur Acad Dermatol Venereol. 2024;38:1687\u201393.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1539_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jid.2020.08.020","volume":"141","author":"KA Whang","year":"2021","unstructured":"Whang KA, Khanna R, Williams KA, Mahadevan V, Semenov Y, Kwatra SG. Health-related QOL and economic burden of chronic pruritus. J Invest Dermatol. 2021;141:754-760.e1.","journal-title":"J Invest Dermatol"},{"key":"1539_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2340\/00015555-3164","volume":"99","author":"E Weisshaar","year":"2019","unstructured":"Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019;99:469\u2013506.","journal-title":"Acta Derm Venereol"},{"key":"1539_CR9","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/all.16009","volume":"79","author":"S M\u00fcller","year":"2024","unstructured":"M\u00fcller S, Maintz L, Bieber T. Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs. Allergy. 2024;79:1501\u201315.","journal-title":"Allergy"},{"key":"1539_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00687-7","author":"U Beuers","year":"2023","unstructured":"Beuers U, Wolters F, Oude Elferink RPJ. Mechanisms of pruritus in cholestasis: understanding and treating the itch. Nat Rev Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1038\/s41575-022-00687-7.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1539_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40620-025-02221-9","volume":"38","author":"T Wang","year":"2025","unstructured":"Wang T, Goh JX, Seth S, et al. Chronic kidney disease-associated pruritus and patient-centred outcomes: a systematic review. J Nephrol. 2025;38:371\u201391.","journal-title":"J Nephrol"},{"key":"1539_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s10157-021-02047-2","volume":"25","author":"E Kinugasa","year":"2021","unstructured":"Kinugasa E, Igawa K, Shimada H, et al. Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase\u00a0II, randomized, double-blind, placebo-controlled clinical study. Clin Exp Nephrol. 2021;25:875\u201384.","journal-title":"Clin Exp Nephrol"},{"key":"1539_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057596","volume":"12","author":"B L\u00f6we","year":"2022","unstructured":"L\u00f6we B, Andresen V, van den Bergh O, et al. Persistent SOMAtic symptoms ACROSS diseases \u2013 from risk factors to modification: scientific framework and overarching protocol of the interdisciplinary SOMACROSS research unit (RU 5211). BMJ Open. 2022;12:e057596.","journal-title":"BMJ Open"},{"key":"1539_CR14","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/S0140-6736(24)00623-8","volume":"403","author":"B L\u00f6we","year":"2024","unstructured":"L\u00f6we B, Toussaint A, Rosmalen JGM, et al. Persistent physical symptoms: definition, genesis, and management. Lancet. 2024;403:2649\u201362.","journal-title":"Lancet"},{"key":"1539_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-060811","volume":"12","author":"G Schneider","year":"2022","unstructured":"Schneider G, St\u00e4nder S, Kahnert S, et al. Biological and psychosocial factors associated with the persistence of pruritus symptoms: protocol for a prospective, exploratory observational study in Germany (individual project of the Interdisciplinary SOMACROSS Research Unit RU 5211). BMJ Open. 2022;12:e060811.","journal-title":"BMJ Open"},{"key":"1539_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101140","volume":"48","author":"A Toussaint","year":"2025","unstructured":"Toussaint A, Weigel A, L\u00f6we B. The overlooked burden of persistent physical symptoms: a call for action in European healthcare. Lancet Reg Health Eur. 2025;48:101140.","journal-title":"Lancet Reg Health Eur"},{"key":"1539_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00403-009-0928-8","volume":"301","author":"M Augustin","year":"2009","unstructured":"Augustin M, Radtke MA, Zschocke I, et al. The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res. 2009;301:561\u201371.","journal-title":"Arch Dermatol Res"},{"key":"1539_CR18","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/j.1365-2133.2009.09328.x","volume":"161","author":"C Blome","year":"2009","unstructured":"Blome C, Augustin M, Siepmann D, Phan NQ, Rustenbach SJ, St\u00e4nder S. Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool. Br J Dermatol. 2009;161:1143\u20138.","journal-title":"Br J Dermatol"},{"key":"1539_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1159\/000520863","volume":"238","author":"S St\u00e4nder","year":"2022","unstructured":"St\u00e4nder S, Garbe C, Hagenstr\u00f6m K, Petersen J, Zeidler C, Augustin M. Healthcare utilization and treatment patterns in patients with chronic prurigo and chronic pruritus in Germany. Dermatology. 2022;238:753\u201361.","journal-title":"Dermatology"},{"key":"1539_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000446009","volume":"50","author":"S St\u00e4nder","year":"2016","unstructured":"St\u00e4nder S. Classification of itch. Curr Probl Dermatol. 2016;50:1\u20134.","journal-title":"Curr Probl Dermatol"},{"key":"1539_CR21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2340\/00015555-1246","volume":"92","author":"NQ Phan","year":"2012","unstructured":"Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92:502\u20137.","journal-title":"Acta Derm Venereol"},{"key":"1539_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1539_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2340\/00015555-2782","volume":"98","author":"A Stumpf","year":"2018","unstructured":"Stumpf A, Pfleiderer B, Fritz F, Osada N, Chen SC, St\u00e4nder S. Assessment of quality of life in chronic pruritus: relationship between ItchyQoL and dermatological life quality index in 1,150 patients. Acta Derm Venereol. 2018;98:142\u20133.","journal-title":"Acta Derm Venereol"},{"key":"1539_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0022-3999(96)00216-4","volume":"42","author":"C Herrmann","year":"1997","unstructured":"Herrmann C. International experiences with the Hospital Anxiety and Depression Scale\u2013a review of validation data and clinical results. J Psychosom Res. 1997;42:17\u201341.","journal-title":"J Psychosom Res"},{"key":"1539_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000600","author":"PC Zimbrean","year":"2025","unstructured":"Zimbrean PC, Jakab SS. Depression and anxiety management in cirrhosis. Hepatol Commun. 2025. https:\/\/doi.org\/10.1097\/HC9.0000000000000600.","journal-title":"Hepatol Commun"},{"key":"1539_CR26","volume":"23","author":"M Garcia-Altieri","year":"2024","unstructured":"Garcia-Altieri M, Carrera-Mejias K, Hernaez R. Management of depression\/anxiety in patients with chronic liver disease. Clin Liver Dis (Hoboken). 2024;23:e0179.","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"1539_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/IJNRD.S126615","volume":"11","author":"ZS Goh","year":"2018","unstructured":"Goh ZS, Griva K. Anxiety and depression in patients with end-stage renal disease: impact and management challenges \u2013 a narrative review. Int J Nephrol Renovasc Dis. 2018;11:93\u2013102.","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"1539_CR28","doi-asserted-by":"publisher","first-page":"909","DOI":"10.14309\/ajg.0000000000003158","volume":"120","author":"NN Ufere","year":"2025","unstructured":"Ufere NN, Zeng C, Donlan J, et al. Psychological distress is prevalent and interdependent among patients with decompensated cirrhosis and their caregivers. Am J Gastroenterol. 2025;120:909\u201313.","journal-title":"Am J Gastroenterol"},{"key":"1539_CR29","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1038\/s41467-023-38013-7","volume":"14","author":"X Gao","year":"2023","unstructured":"Gao X, Geng T, Jiang M, et al. Accelerated biological aging and risk of depression and anxiety: evidence from 424,299 UK Biobank participants. Nat Commun. 2023;14:2277.","journal-title":"Nat Commun"},{"key":"1539_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-021-02349-3","volume":"22","author":"Z Al Naamani","year":"2021","unstructured":"Al Naamani Z, Gormley K, Noble H, Santin O, Al Maqbali M. Fatigue, anxiety, depression and sleep quality in patients undergoing haemodialysis. BMC Nephrol. 2021;22:157.","journal-title":"BMC Nephrol"},{"key":"1539_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000588","volume":"8","author":"C Zeng","year":"2024","unstructured":"Zeng C, Donlan J, Indriolo T, et al. Validation of the hospital anxiety and depression scale in patients with decompensated cirrhosis. Hepatol Commun. 2024;8:e0588.","journal-title":"Hepatol Commun"},{"key":"1539_CR32","doi-asserted-by":"publisher","first-page":"566","DOI":"10.4103\/1319-2442.388191","volume":"33","author":"T Aatif","year":"2022","unstructured":"Aatif T, Achour I, Arache W, et al. Anxiety and depression disorders in adults on chronic hemodialysis. Saudi J Kidney Dis Transpl. 2022;33:566\u201373.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"1539_CR33","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.3962","volume":"103","author":"S Schlachter","year":"2023","unstructured":"Schlachter S, Sommer R, Augustin M, Tsianakas A, Westphal L. A comparative analysis of the predictors, extent and impacts of self-stigma in patients with Psoriasis and Atopic Dermatitis. Acta Derm Venereol. 2023;103:adv3962.","journal-title":"Acta Derm Venereol"},{"key":"1539_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121:340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1539_CR35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/pde.12802","volume":"33","author":"CM Nguyen","year":"2016","unstructured":"Nguyen CM, Koo J, Cordoro KM. Psychodermatologic effects of atopic dermatitis and acne: a review on self-esteem and identity. Pediatr Dermatol. 2016;33:129\u201335.","journal-title":"Pediatr Dermatol"},{"key":"1539_CR36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjd.14910","volume":"176","author":"S Steinke","year":"2017","unstructured":"Steinke S, Bruland P, Blome C, et al. Chronic pruritus: evaluation of patient needs and treatment goals with a special regard to differences according to pruritus classification and sex. Br J Dermatol. 2017;176:363\u201370.","journal-title":"Br J Dermatol"},{"key":"1539_CR37","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.2922","volume":"103","author":"S-P Sinikumpu","year":"2023","unstructured":"Sinikumpu S-P, Jokelainen J, Tasanen K, Timonen M, Huilaja L. Association between pruritus and psychosocial well-being: a population-based study among 6,809 subjects. Acta Derm Venereol. 2023;103:adv00837.","journal-title":"Acta Derm Venereol"},{"key":"1539_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jdin.2021.02.004","volume":"3","author":"J Lee","year":"2021","unstructured":"Lee J, Suh H, Jung H, Park M, Ahn J. Association between chronic pruritus, depression, and insomnia: a cross-sectional study. JAAD Int. 2021;3:54\u201360.","journal-title":"JAAD Int"},{"key":"1539_CR39","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.8488","volume":"103","author":"BR Ferreira","year":"2023","unstructured":"Ferreira BR, Misery L. Psychopathology associated with chronic pruritus: a systematic review. Acta Derm Venereol. 2023;103:adv8488.","journal-title":"Acta Derm Venereol"},{"key":"1539_CR40","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2331613","volume":"46","author":"L Zhang","year":"2024","unstructured":"Zhang L, Zou L, Zhou L. Effectiveness of psychoeducational interventions on psychological distress and health-related quality of life among patients with maintenance hemodialysis: a systematic review and meta-analysis. Ren Fail. 2024;46:2331613.","journal-title":"Ren Fail"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01539-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01539-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01539-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T17:17:51Z","timestamp":1761239871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01539-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1539"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01539-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Svenja Royeck was advisor, speaker or investigator for Incyte Inc., Eli Lilly, LEO Pharma and Sanofi\/Regeneron outside the submitted work. Christian Mess, Meike Shedden Mora, Tobias B. Huber, Felix Witte, Konstantin Agelopoulos, Henning Wiegmann and Johannes B. Oehm have nothing to disclose. Angelika Weigel reports research funding (no personal honoraria) from the Werner Otto Foundation. She has received remunerations for a lecture at the Lindauer Psychotherapietage and she has been treasurer of the EAPM (unpaid) until 2023. Volker Huck has received research funding from LEO Pharma GmbH in terms of an investigator-initiated trial outside the submitted work. Bernd L\u00f6we reports research funding (no personal honoraria) from the German Research Foundation, the German Federal Ministry of Education and Research, the German Innovation Committee at the Joint Federal Committee, the European Commission\u2019s Horizon 2020 Framework Programme, the European Joint Programme for Rare Diseases (EJP), the Ministry of Science, Research and Equality of the Free and Hanseatic City of Hamburg, Germany and the Foundation Psychosomatics of Spinal Diseases, Stuttgart, Germany. He received remunerations for several scientific book articles from various book publishers, from the Norddeutscher Rundfunk (NDR) for interviews in medical knowledge programmes on public television, and as a committee member from Aarhus University, Denmark. He received travel expenses from the European Association of Psychosomatic Medicine (EAPM), and accommodation and meals from the Societatea de Medicina Biopsyhosociala, Romania, for a presentation at the EAPM Academy at the Conferin\u021ba Na\u021bional\u0103 de Psihosomatic\u0103, Cluj-Napoca, Romania, October 2023. He received a travel grant for a lecture on the occasion of the presentation of the Alison Creed Award at the EAPM Conference in Lausanne, 12\u201315 June 2024. He received remuneration and travel expenses for lecture at the Lindauer Psychotherapiewochen, April 2024. He is President of the German College of Psychosomatic Medicine (DKPM) (unpaid) since March 2024 and was a member of the Board of the European Association of Psychosomatic Medicine (EAPM) (unpaid) until 2022. He is member of the EIFFEL Study Oversight Committee (unpaid). Anne Toussaint reports research funding (no personal honoraria) from the German Research Foundation. She has received remunerations for a printed textbook from Ernst Reinhardt Publishing. The other authors have no conflict of interest to declare. Christoph Schramm was consultant for Pliant Therapeutics, Chemomab, Agomab, Amgen and Moonlake and received honoraria for lectures from Falk Foundation. Claudia Zeidler is an investigator for Novartis, Janssen, Pfizer, UCB, Lilly, Abbvie, Boehringer Ingelheim, Sanofi, Regeneron, Leo, Galderma and has received speaker honoraria\/travel fees from Dermasence, Beiersdorf, Leo, Sanofi, Novartis, Unna Akademie, Almirall and AbbVie outside the submitted work. Matthias Augustin has served as a consultant or paid speaker or has received research grants or honoraria for consulting and scientific presentations or has received travel reimbursements or participated in clinical trials for companies that manufacture drugs for the treatment of pruritus\/prurigo, including AbbVie, Almirall, Eli Lilly, Galderma, Novartis, Pfizer, Sanofi and Trevi. Stefan W. Schneider was speaker and\/or consultant funding from Almirall S. A., GSK R&D Ltd., Incyte Corporation, LEO Pharma GmbH, Lilly Deutschland GmbH, Novartis Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Pfizer Pharma GmbH. Sonja St\u00e4nder was speaker and\/or consultant and\/or Investigator and\/or has received research funding from Amgen Inc., Almirall S. A., Celldex Therapeutics Inc., Clexio Biosciences Ltd., Focus-Insight Healthtech Group Co. Ltd., Galderma Laboratorium GmbH, Galderma R & D, LLC., Galderma SA, Klirna Biotech Inc., GSK R&D Ltd., Incyte Corporation, LEO Pharma GmbH, Lilly Deutschland GmbH, Novartis Pharma GmbH, P. G. Unna Academy, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis R& D, Sanofi Genzyme Corporation, TouchIME, Vifor Pharma Deutschland GmbH. Sonja St\u00e4nder is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Sonja St\u00e4nder was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Reviewed and approved by the Ethics Committee of the State Medical Association of Westfalen-Lippe, M\u00fcnster, Germany; approval # 2007-413-f-S.\u00a0All participants provided written informed consent prior to their inclusion in the research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}